KindlyMD, Inc. (NASDAQ:NAKA) Receives $30.00 Average Target Price from Analysts

Shares of KindlyMD, Inc. (NASDAQ:NAKA) have been assigned an average rating of “Hold” from the five analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $30.00.

Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded KindlyMD to a “sell” rating in a research report on Saturday, May 23rd. B. Riley Financial decreased their target price on KindlyMD from $40.00 to $20.00 and set a “buy” rating for the company in a research report on Monday, February 23rd. Weiss Ratings upgraded KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. TD Cowen assumed coverage on KindlyMD in a research report on Friday, April 10th. They set a “buy” rating and a $40.00 target price for the company. Finally, Maxim Group decreased their target price on KindlyMD from $60.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, April 6th.

KindlyMD Trading Down 0.2%

KindlyMD stock opened at $4.96 on Friday. The firm has a market capitalization of $86.30 million, a P/E ratio of -0.11 and a beta of 15.84. KindlyMD has a 1 year low of $4.50 and a 1 year high of $808.00. The business has a 50-day moving average of $7.86 and a 200-day moving average of $12.45.

KindlyMD (NASDAQ:NAKA) last posted its earnings results on Wednesday, May 13th. The company reported ($15.20) earnings per share (EPS) for the quarter. The company had revenue of $2.68 million for the quarter. KindlyMD had a negative return on equity of 81.32% and a negative net margin of 7,397.12%. Research analysts anticipate that KindlyMD will post -16.8 EPS for the current fiscal year.

Insider Activity

In other KindlyMD news, CEO David F. Bailey acquired 104,833 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The stock was acquired at an average cost of $4.84 per share, for a total transaction of $507,391.72. Following the transaction, the chief executive officer owned 3,120,361 shares of the company’s stock, valued at $15,102,547.24. This trade represents a 3.48% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders purchased 191,448 shares of company stock valued at $992,908. 24.49% of the stock is currently owned by insiders.

Hedge Funds Weigh In On KindlyMD

Several institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC grew its position in shares of KindlyMD by 76.2% in the 2nd quarter. Geode Capital Management LLC now owns 19,394 shares of the company’s stock valued at $484,000 after purchasing an additional 8,386 shares during the period. Osaic Holdings Inc. acquired a new position in shares of KindlyMD in the 2nd quarter valued at approximately $215,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of KindlyMD in the 3rd quarter valued at approximately $369,000. Tower Research Capital LLC TRC grew its position in shares of KindlyMD by 1,638.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 33,152 shares of the company’s stock valued at $827,000 after purchasing an additional 31,245 shares during the period. Finally, CI Investments Inc. acquired a new position in shares of KindlyMD in the 3rd quarter valued at approximately $995,000.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.